Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29443087 | 0.89 | ACE (0.55) | ACE | |
| SCHEMBL31092820 | 0.89 | ACE (0.55) | ACE | |
| SCHEMBL29545684 | 0.89 | ACE (0.55) | ACE | |
| SCHEMBL927332 | 0.89 | ACE (0.55) | ACE | |
| SCHEMBL3702462 | 0.89 | ACE (0.55) | ACE | |
| SCHEMBL705456 | 0.89 | ACE (0.55) | ACE | |
| SCHEMBL17032680 | 0.86 | NOTUM (0.50) | NOTUMACE | |
| SCHEMBL12474854 | 0.85 | LMNA (0.47) | — | |
| SCHEMBL27744374 | 0.85 | XIAP (0.49) | NOTUM | |
| SCHEMBL7950930 | 0.84 | ACE (0.51) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9758537-B2 | Compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170189410-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20150239838-A1 | Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239838-A1 | Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, CFH | NOTUM 3598/4885ACE 946/4885 |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C1QBP | NOTUM 3847/4885ACE 2043/4885 |
| US-20170189410-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | NOTUM 4119/4885ACE 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.